Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large gene delivery via adeno-associated viral vector is a gene therapy approach used to deliver therapeutic genes larger than the standard AAV packaging capacity. It utilizes strategies such as dual or multi-vector systems to overcome size limitations and treat diseases caused by mutations in large genes, such as dystrophin in Duchenne muscular dystrophy.
AAV vectors deliver DNA sequences encoding therapeutic proteins into host cells. The delivered DNA typically remains episomal. After infection, the transgene is expressed by the host cell machinery using dual/multi-vector systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large Gene Delivery via Adeno-Associated Viral Vector (rAAV Large Gene Delivery).